LAMTOR2 Gene

📖 Wiki Page

gene1242 wordssynced 2026-04-02

MLST8 Protein

<table class="infobox infobox-gene">
<tr>
<th class="infobox-header" colspan="2">LAMTOR2 Gene</th>
</tr>
<tr>
<td class="label">Protein Name</td>
<td>MLST8</td>
</tr>
<tr>
<td class="label">Gene Symbol</td>
<td>MLST8</td>
</tr>
<tr>
<td class="label">Full Name</td>
<td>MTOR Associated Protein, LST8 Homolog</td>
</tr>
<tr>
<td class="label">UniProt ID</td>
<td>Q8BXR0 (Mouse), Q9BVA0 (Human)</td>
</tr>
<tr>
<td class="label">Gene ID</td>
<td>84916 (Human)</td>
</tr>
<tr>
<td class="label">Molecular Weight</td>
<td>~36 kDa</td>
</tr>
<tr>
<td class="label">Subcellular Localization</td>
<td>Lysosomal membrane, cytoplasm</td>
</tr>
<tr>
<td class="label">Protein Family</td>
<td>LST8/MLST8 family</td>
</tr>
<tr>
<td class="label">Tissue Expression</td>
<td>Ubiquitous; highest in brain, heart, skeletal muscle</td>
</tr>
<tr>
<td class="label">Drug</td>
<td>Type</td>
</tr>
<tr>
<td class="label">Rapamycin (Sirolimus)</td>
<td>Allosteric</td>
</tr>
<tr>
<td class="label">Everolimus</td>
<td>Allosteric</td>
</tr>
<tr>
<td class="label">Torin 1</td>
<td>ATP-competitive</td>
</tr>
<tr>
<td class="label">AZD8055</td>
<td>ATP-competitive</td>
</tr>
<tr>
<td class="label">KG Connections</td>
<td><a href="/atlas" style="color:#4fc3f7">4 edges</a></td>
</tr>
</table>

Introduction

...

MLST8 Protein

Introduction

MLST8 ([MTOR](/mechanisms/mtor-signaling-pathway) Associated Protein, LST8 Homolog) is a critical component of both mTORC1 and mTORC2 complexes and plays important roles in neurodegenerative diseases. This page provides comprehensive information about its structure, function, and therapeutic implications. [@discovery]

Overview

Mermaid diagram (expand to render)

MLST8 is a conserved protein component of the mechanistic Target of Rapamycin (mTOR) kinase complexes. As a core subunit, MLST8 provides structural support and helps regulate the kinase activity of both mTORC1 and mTORC2. Targeting MLST8 and [mTOR](/entities/mtor) signaling has significant therapeutic potential in neurodegenerative diseases. [@mtor]

Protein Information

Structure

MLST8 contains several key structural features:

WD40 Repeat Domains: Seven WD40 repeats form a beta-propeller structure that mediates protein-protein interactions
Beta-Propeller Structure: Provides a stable scaffold for complex formation
HEAT Repeats: Facilitate interactions with other mTOR complex components
Phosphorylation Sites: Multiple serine/threonine phosphorylation sites regulate function

The structure allows MLST8 to serve as a scaffolding protein that stabilizes both mTORC1 and mTORC2 complexes.

Molecular Function

MLST8 is essential for mTOR complex function and structure:

mTORC1 Function

Structural Stabilization: Maintains mTORC1 integrity
Kinase Activity Enhancement: Amplifies mTOR catalytic activity
Substrate Recruitment: Facilitates substrate access to the kinase domain
RAPTOR Interaction: Works with RAPTOR to regulate mTORC1 signaling

mTORC2 Function

Complex Assembly: Required for proper mTORC2 formation
Kinase Activation: Essential for mTORC2 autophosphorylation
AKT Activation: Mediates AKT phosphorylation at Ser473
RICTOR Interaction: Partners with RICTOR for mTORC2 function

Expression Pattern

MLST8 exhibits broad tissue expression with notable levels in the nervous system:

Brain Regions

Cerebral [Cortex](/brain-regions/cortex): High expression in pyramidal [neurons](/entities/neurons)
[Hippocampus](/brain-regions/hippocampus): Particularly in CA1-CA3 regions
Cerebellum: Purkinje cells show significant expression
Basal Ganglia: Moderate expression in striatal neurons

Cellular Localization

Synaptic Compartments: Presynaptic terminals and postsynaptic densities
Dendrites and Axons: Cytosolic and membrane-associated pools
Lysosomal Membrane: Critical for mTORC1 localization
Cytoplasm: General cytoplasmic distribution

Disease Associations

Alzheimer's Disease

MLST8 and mTOR signaling are critically involved in Alzheimer's disease pathogenesis:

mTORC1 Hyperactivation: Elevated mTORC1 activity in AD brains correlates with cognitive decline
[Autophagy](/entities/autophagy) Impairment: mTORC1 inhibits autophagy, leading to accumulated protein aggregates ([amyloid-beta](/proteins/amyloid-beta), tau)
Synaptic Plasticity Deficits: mTOR dysregulation affects [long-term potentiation](/mechanisms/long-term-potentiation) ([LTP](/mechanisms/long-term-potentiation))
Memory Impairment: mTORC1 hyperactivation impairs memory consolidation
Therapeutic Targeting: mTOR inhibitors show promise in preclinical AD models

Key References:

PMID: 25396082(https://pubmed.ncbi.nlm.nih.gov/25396082/) - mTOR signaling in Alzheimer's disease
PMID: 26255403(https://pubmed.ncbi.nlm.nih.gov/26255403/) - Autophagy and neurodegeneration

Parkinson's Disease

MLST8/mTOR signaling plays a complex role in PD:

[Alpha-Synuclein](/mechanisms/alpha-synuclein) Metabolism: mTOR regulates autophagy of [alpha-synuclein](/proteins/alpha-synuclein) aggregates
Mitochondrial Dysfunction: mTORC2/PI3K/AKT pathway affects mitochondrial health
Dopaminergic Neuron Survival: mTOR activity influences neuronal viability
LRRK2 Interaction: G2019S LRRK2 mutation affects mTOR signaling

Key References:

PMID: 26925799(https://pubmed.ncbi.nlm.nih.gov/26925799/) - mTOR in Parkinson's disease models
PMID: 28749530(https://pubmed.ncbi.nlm.nih.gov/28749530/) - Autophagy and alpha-synuclein

Tuberous Sclerosis Complex (TSC)

mTORC1 Hyperactivation: TSC1/TSC2 mutations cause constitutive mTORC1 activation
Neurological Manifestations: Seizures, intellectual disability, autism
Rapamycin Treatment: mTOR inhibitors effectively reduce tumor growth and seizures

Amyotrophic Lateral Sclerosis (ALS)

mTOR Dysregulation: Observed in ALS patient tissues and models
Autophagy Defects: Impaired clearance of mutant proteins (SOD1, FUS, TDP-43)
Therapeutic Potential: mTOR modulation may benefit ALS patients

Signaling Pathways

mTORC1 Pathway

Amino Acids → Rag GTPases → mTORC1 (RAPTOR) → S6K1/4E-BP1
↓
Protein Synthesis, Autophagy

mTORC2 Pathway

Growth Factors → PI3K → PDK1 → AKT → mTORC2 (RICTOR)
↓
AKT (Ser473), PKCα, SGK1

Therapeutic Implications

mTOR Inhibitors

Autophagy Inducers

Trehalose: mTOR-independent autophagy inducer
Resveratrol: SIRT1 activator, modulates mTOR
Metformin: AMPK activator, indirectly reduces mTORC1
Lithium: Autophagy enhancer via IMPase inhibition

Neuroprotective Strategies

Combination Therapy: mTOR inhibitors with autophagy inducers
Temporal Regulation: Intermittent dosing to avoid side effects
Targeted Delivery: Nanoparticle-based brain delivery
Biomarker Monitoring: Track p-S6 levels for response

Animal Models

Knockout Models

Mlst8 Constitutive Knockout: Viable with mild metabolic phenotypes
Conditional Neuronal Knockout: Leads to impaired synaptic function
Muscle-specific Knockout: Affects metabolism and function

Transgenic Models

MLST8 Overexpression: Accelerates tumor growth
mTORC1 Activation: Phenocopies TSC deficiency

Interaction Network

MLST8 interacts with multiple proteins:

Core mTOR Complex Partners

mTOR: Kinase catalytic subunit
RAPTOR: mTORC1-specific scaffolding protein
RICTOR: mTORC2-specific scaffolding protein
mLST8: Same protein (homodimerization)

Downstream Effectors

S6K1 (RPS6KB1): Phosphorylation target
4E-BP1 (EIF4EBP1): Translation repressor
AKT (PKB): Phosphorylation by mTORC2
PKCα: Phosphorylation target

Regulators

TSC1/TSC2: Rheb GTPase-activating complex
Rag GTPases: Amino acid sensing
PRAS40: mTORC1 inhibitor

Clinical Relevance

Biomarkers

Phospho-S6 (Ser240/244): Readout of mTORC1 activity
Phospho-AKT (Ser473): Readout of mTORC2 activity
LC3-II: Autophagy flux marker

Clinical Trials

Rapamycin for Alzheimer's disease (NCT04629443)
Everolimus for TSC-associated seizures
AZD8055 for solid tumors (completed)

Research Directions

Emerging Areas

mTORC1/C2 Specific Targeting: Developing isoform-selective inhibitors
Age-related mTOR Dysregulation: Understanding circadian regulation
[Blood-Brain Barrier](/entities/blood-brain-barrier) Penetration: Improving drug delivery
Personalized Medicine: Genetic stratification for treatment

Unresolved Questions

Optimal dosing regimens for neurodegenerative diseases
Long-term safety of chronic mTOR inhibition
Biomarkers for treatment response
Combination therapy protocols

History

The discovery of MLST8 as an mTOR component followed the identification of mTOR itself:

1991: mTOR identified as the target of rapamycin
1994: mTORC1 and mTORC2 complexes characterized
2002: MLST8 identified as shared component
2007: Crystal structure of mTOR kinase domain solved
2010s: mTOR roles in neurodegeneration extensively studied

Background

The study of Lamtor2 Gene has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.

Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.

External Links

[NCBI Gene MLST8](https://www.ncbi.nlm.nih.gov/gene/84916)
[UniProt Q9BVA0](https://www.uniprot.org/uniprotkb/Q9BVA0)
[HGNC: MLST8](https://www.genenames.org/data/hgnc_data.php?hgnc_id=29789)
[Gene Ontology: MLST8](https://amigo.geneontology.org/amigo/term/GO:0005829)

References

[Unknown, - Discovery of mTORC1 structure (n.d.)](https://pubmed.ncbi.nlm.nih.gov/12150926/)

[Unknown, - mTOR in Alzheimer's disease pathogenesis (n.d.)](https://pubmed.ncbi.nlm.nih.gov/25396082/)

[Unknown, - Autophagy mechanisms in neurodegeneration (n.d.)](https://pubmed.ncbi.nlm.nih.gov/26255403/)

[Unknown, - mTOR signaling in Parkinson's disease (n.d.)](https://pubmed.ncbi.nlm.nih.gov/26925799/)

[Unknown, - Alpha-synuclein and autophagy (n.d.)](https://pubmed.ncbi.nlm.nih.gov/28749530/)

[Unknown, - mTORC2 structure and function (n.d.)](https://pubmed.ncbi.nlm.nih.gov/22586121/)

[Unknown, - WD40 repeat protein structures (n.d.)](https://pubmed.ncbi.nlm.nih.gov/19339617/)

[Unknown, - mTOR inhibitors in neurological disorders (n.d.)](https://pubmed.ncbi.nlm.nih.gov/24464289/)

[Unknown, - Rapamycin and longevity (n.d.)](https://pubmed.ncbi.nlm.nih.gov/25939662/)

[Unknown, - Autophagy induction for neurodegeneration (n.d.)](https://pubmed.ncbi.nlm.nih.gov/28615654/)

📖 View canonical wiki page →

LAMTOR2 Gene

MLST8 Protein

Introduction

MLST8 Protein

Introduction

Overview

Protein Information

Structure

Molecular Function

mTORC1 Function

mTORC2 Function

Expression Pattern

Brain Regions

Cellular Localization

Disease Associations

Alzheimer's Disease

Parkinson's Disease

Tuberous Sclerosis Complex (TSC)

Amyotrophic Lateral Sclerosis (ALS)

Signaling Pathways

mTORC1 Pathway

mTORC2 Pathway

Therapeutic Implications

mTOR Inhibitors

Autophagy Inducers

Neuroprotective Strategies

Animal Models

Knockout Models

Transgenic Models

Interaction Network

Core mTOR Complex Partners

Downstream Effectors

Regulators

Clinical Relevance

Biomarkers

Clinical Trials

Research Directions

Emerging Areas

Unresolved Questions

History

See Also

Background

External Links

References